| Biological Sciences | Lifetime | 146 | IT 2 | 99.98 |
| Biological Sciences | 2021-2025 | 2 | IT 1 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 65 | IT 6 | 99.99 |
| Genetics | Lifetime | 13 | IT 1 | 99.96 |
| Epidemiology | Lifetime | 198 | IT 7 | 99.75 |
| Immunology | Lifetime | 195 | IT 7 | 99.55 |
| Surgery | Lifetime | 643 | IT 25 | 99.40 |
| Oncology | Lifetime | 636 | IT 25 | 98.75 |
| Hematology | Lifetime | 590 | IT 34 | 95.53 |
| Gastroenterology | Lifetime | 354 | IT 28 | 94.49 |
| Medical Genetics | Lifetime | 981 | IT 56 | 86.56 |
| Hepatology | Lifetime | 897 | IT 66 | 78.25 |
| Genetics | 2021-2025 | 1 | IT 1 | 99.99 |
| Epidemiology | 2021-2025 | 20 | IT 2 | 99.92 |
| Surgery | 2021-2025 | 46 | IT 5 | 99.74 |
| Immunology | 2021-2025 | 27 | IT 2 | 99.41 |
| Gastroenterology | 2021-2025 | 40 | IT 2 | 97.73 |
| Oncology | 2021-2025 | 247 | IT 15 | 97.91 |
| Rheumatology | 2021-2025 | 183 | IT 17 | 95.14 |
| Medical Genetics | 2021-2025 | 175 | IT 17 | 92.80 |
| Public, Environmental and Occupational Health | 2021-2025 | 846 | IT 30 | 91.41 |
| Infectious Diseases | 2021-2025 | 459 | IT 27 | 90.27 |
| Speech and Hearing | 2021-2025 | 139 | IT 3 | 85.58 |
| Hepatology | 2021-2025 | 284 | IT 29 | 81.08 |
| Biosimilars and Bioanalytical Methods | Lifetime | 1 | IT 1 | 99.90 |
| COVID-19 and healthcare impacts | Lifetime | 10 | IT 3 | 99.53 |
| Inflammatory Bowel Disease | Lifetime | 8 | IT 1 | 99.95 |
| Microscopic Colitis | Lifetime | 7 | IT 1 | 99.94 |
| Autoimmune and Inflammatory Disorders | Lifetime | 8 | IT 1 | 99.90 |
| Eosinophilic Esophagitis | Lifetime | 27 | IT 2 | 99.76 |
| COVID-19 Clinical Research Studies | Lifetime | 86 | IT 8 | 99.41 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 50 | IT 5 | 99.61 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 44 | IT 1 | 99.70 |
| Pregnancy and Medication Impact | Lifetime | 23 | IT 1 | 99.41 |
| Pharmaceutical studies and practices | Lifetime | 62 | IT 2 | 99.13 |
| IL-33, ST2, and ILC Pathways | Lifetime | 56 | IT 3 | 99.27 |
| Diagnosis and treatment of tuberculosis | Lifetime | 75 | IT 4 | 98.84 |
| Celiac Disease Research and Management | Lifetime | 61 | IT 11 | 98.73 |
| Diverticular Disease and Complications | Lifetime | 111 | IT 8 | 98.80 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 133 | IT 8 | 98.97 |
| Liver Diseases and Immunity | Lifetime | 113 | IT 8 | 98.79 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 514 | IT 11 | 98.71 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 253 | IT 5 | 98.43 |
| Cell Adhesion Molecules Research | Lifetime | 557 | IT 16 | 98.28 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 609 | IT 52 | 98.45 |
| Mycobacterium research and diagnosis | Lifetime | 488 | IT 12 | 97.59 |
| Pharmacological Effects of Natural Compounds | Lifetime | 407 | IT 8 | 97.22 |
| Systemic Lupus Erythematosus Research | Lifetime | 615 | IT 45 | 98.20 |
| Appendicitis Diagnosis and Management | Lifetime | 280 | IT 20 | 97.49 |
| Angiogenesis and VEGF in Cancer | Lifetime | 571 | IT 34 | 96.71 |
| Chemokine receptors and signaling | Lifetime | 410 | IT 35 | 94.60 |
| Lymphatic System and Diseases | Lifetime | 492 | IT 20 | 91.37 |
| Sphingolipid Metabolism and Signaling | Lifetime | 718 | IT 26 | 91.07 |
| Medical and Biological Ozone Research | Lifetime | 434 | IT 47 | 87.60 |
| Biomarkers in Disease Mechanisms | Lifetime | 573 | IT 79 | 85.44 |
| Inflammation biomarkers and pathways | Lifetime | 436 | IT 10 | 81.18 |
| Whipple's Disease and Interleukins | Lifetime | 576 | IT 31 | 63.67 |
| Inflammatory Bowel Disease | 2021-2025 | 1 | IT 1 | 99.99 |
| Microscopic Colitis | 2021-2025 | 1 | IT 1 | 100.00 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 1 | IT 1 | 99.91 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 1 | IT 1 | 99.82 |
| Eosinophilic Esophagitis | 2021-2025 | 2 | IT 2 | 99.85 |
| Pregnancy and Medication Impact | 2021-2025 | 1 | IT 1 | 99.45 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 3 | IT 1 | 99.89 |
| Celiac Disease Research and Management | 2021-2025 | 2 | IT 1 | 99.11 |
| Diverticular Disease and Complications | 2021-2025 | 4 | IT 2 | 99.15 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 3 | IT 1 | 99.74 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 37 | IT 3 | 99.39 |
| Pharmaceutical studies and practices | 2021-2025 | 11 | IT 1 | 98.52 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 11 | IT 1 | 97.44 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 19 | IT 3 | 98.13 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 13 | IT 2 | 97.39 |
| Liver Diseases and Immunity | 2021-2025 | 25 | IT 3 | 98.96 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 41 | IT 4 | 98.63 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 152 | IT 9 | 98.05 |
| Mycobacterium research and diagnosis | 2021-2025 | 69 | IT 3 | 96.40 |
| Appendicitis Diagnosis and Management | 2021-2025 | 60 | IT 19 | 96.00 |
| Gastrointestinal disorders and treatments | 2021-2025 | 110 | IT 11 | 95.58 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 115 | IT 2 | 94.15 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 262 | IT 39 | 96.63 |
| Tuberculosis Research and Epidemiology | 2021-2025 | 272 | IT 8 | 95.72 |
| Adolescent and Pediatric Healthcare | 2021-2025 | 176 | IT 7 | 92.83 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 389 | IT 44 | 94.73 |
| Anorectal Disease Treatments and Outcomes | 2021-2025 | 160 | IT 22 | 92.21 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 57 | IT 4 | 90.49 |
| Gastrointestinal motility and disorders | 2021-2025 | 180 | IT 14 | 93.42 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 232 | IT 17 | 91.47 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 673 | IT 31 | 91.47 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 603 | IT 21 | 90.94 |
| Gastroesophageal reflux and treatments | 2021-2025 | 291 | IT 33 | 90.32 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 439 | IT 30 | 89.75 |
| Esophageal and GI Pathology | 2021-2025 | 851 | IT 60 | 90.06 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 911 | IT 95 | 88.02 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 565 | IT 86 | 81.33 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 199 | IT 13 | 73.68 |
| Gastrointestinal Bleeding Diagnosis and Treatment | 2021-2025 | 609 | IT 46 | 71.10 |
| Biliary and Gastrointestinal Fistulas | 2021-2025 | 451 | IT 49 | 69.03 |
| Medical and Biological Ozone Research | 2021-2025 | 972 | IT 110 | 25.35 |